Arq Q1 beats? Strategic review adds uncertainty

What happened

Arq reported Q1 2026 revenue of ~$29M and Adjusted EBITDA of ~$3M, showing modest growth from the prior year. The GAC ramp remains a focus, with a strategic optimization review announced and initial results expected by Q3 2026. While the headline numbers appear stable, the review introduces uncertainty, potentially leading to asset sales or restructuring. However, the company still faces high leverage (~3.2x net debt/EBITDA) and thin interest coverage (~0.5x), leaving little room for error. The strategic review could be a positive catalyst if it results in deleveraging, but it also signals that management is actively seeking solutions to operational and financial challenges.

Implication

The Q1 results are in line with a gradual improvement, but the strategic review is the key development. For investors, the review could lead to asset sales, cost cuts, or a sale of the company, which might unlock value given the current depressed valuation (P/B ~0.6x). However, the review also suggests that management is not satisfied with the organic trajectory, raising questions about the GAC ramp and cash flow generation. Until the review concludes, the stock remains a high-risk, high-reward bet on execution and balance sheet repair. The near-term catalyst is the Q3 2026 update on the review, which could provide clarity on the path forward. Given the lack of detail, we maintain a cautious stance but acknowledge the potential for upside if the review leads to a significant de-levering event.

Thesis delta

The strategic optimization review introduces a new potential catalyst that could unlock value or highlight deeper problems. Previously, the thesis hinged solely on the GAC ramp and PFAS demand; now, management is actively considering structural changes. This adds both risk and optionality, making the stock more binary until the review's outcome is known.